ArticlebioRxiv : the preprint server for biology2025
A NOVEL MACHINE LEARNING APPROACH FOR TUMOR DETECTION BASED ON TELOMERIC SIGNATURES.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
2 authors.
Funding
Abstract
Cancer remains one of the most complex diseases faced by humanity, with over 200 distinct types, each characterized by unique molecular profiles that demand specialized therapeutic approaches (Tomczak et al., 2015). Prior studies have shown that both short and long telomere lengths are associated with elevated cancer risk, underscoring the intricate relationship between telomere length variation and tumorigenesis (The Telomeres Mendelian Randomization Collaboration et al., 2017). To investigate this relationship, we developed a supervised machine learning model trained on telomeric read content, genomic variants, and phenotypic features to predict tumor status. Using data from 33 cancer types within The Cancer Genome Atlas (TCGA) program, our model achieved an accuracy of 82.62% in predicting tumor status. The trained model is available for public use and further development through the project's GitHub repository: https://github.com/paribytes/TeloQuest. This work represents a novel, multidisciplinary approach to improving cancer diagnostics and risk assessment by integrating telomere biology with Biobank-scale genomic and phenotypic data. Furthermore, we highlight the potential of telomere length variation as a meaningful predictive biomarker in oncology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.